Cargando…

Comment to “Telaprevir Experience From Turkey”

Detalles Bibliográficos
Autores principales:	Akar, Tarik, Malkoc, Dilek, Aydemir, Selim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kowsar 2015
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723728/ https://www.ncbi.nlm.nih.gov/pubmed/26834786 http://dx.doi.org/10.5812/hepatmon.29821

Ejemplares similares

Telaprevir-Induced DRESS Syndrome Associated With Salmonella typhi
por: Akar, Tarık, et al.
Publicado: (2015)

Telaprevir Experience From Turkey
por: Komur, Suheyla, et al.
Publicado: (2015)

Telaprevir
Publicado: (2012)

Cutaneous Eruption due to Telaprevir
por: Falcão, Eduardo Mastrangelo Marinho, et al.
Publicado: (2015)

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir
por: Johnson, Mark, et al.
Publicado: (2014)

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy
por: Pradat, Pierre, et al.
Publicado: (2015)

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
por: Karino, Y, et al.
Publicado: (2014)

Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir
por: Gomes, Lenyta Oliveira, et al.
Publicado: (2018)

Thrombosis and Risk Factors: A Comment
por: Akar, Nejat
Publicado: (2012)

Treatment of genotype one hepatitis C virus (HCV) infection in HIV co-infected patients using telaprevir based regimen
por: Siraj, Dawd S., et al.
Publicado: (2014)

Modeling Viral Evolutionary Dynamics after Telaprevir-Based Treatment
por: Haseltine, Eric L., et al.
Publicado: (2014)

Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir
por: D’Ambrosio, Roberta, et al.
Publicado: (2012)

Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C
por: Brogan, Anita J., et al.
Publicado: (2014)

Hantavirus Infection in Istanbul, Turkey
por: Oncul, Oral, et al.
Publicado: (2011)

Telaprevir or boceprevir for hepatitis C treatment: a first survey on pharmacoutilization
por: Capuozzo, Maurizio, et al.
Publicado: (2013)

Pharmacokinetic characteristics of telaprevir in healthy Korean male subjects and comparisons with Japanese
por: Choi, Yewon, et al.
Publicado: (2018)

Chronic Hepatitis C Therapy in Liver Cirrhosis Complicated by Telaprevir-Induced DRESS
por: Mousa, Omar Y. S., et al.
Publicado: (2014)

Formulary Management of the Protease Inhibitors Boceprevir and Telaprevir for Chronic Hepatitis C Virus
por: Tungol, Alexandra, et al.
Publicado: (2011)

Combined immunodeficiencies: twenty years experience from a single center in Turkey
por: Akar, H. Haluk, et al.
Publicado: (2016)

Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment
por: Chantry, AS, et al.
Publicado: (2014)

Hemoglobin H Disease in Turkey: Experience from Eight Centers
por: Ünal, Selma, et al.
Publicado: (2016)

First experiences with the balloon-expandable Myval® transcatheter aortic valve from Turkey
por: Arslan, Uğur, et al.
Publicado: (2020)

Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection
por: Thorlund, Kristian, et al.
Publicado: (2012)

Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir
por: De Meyer, Sandra, et al.
Publicado: (2014)

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C
por: Colombo, M, et al.
Publicado: (2014)

Efficacy and tolerability of telaprevir (TVR)-based triple therapy in HIV/HCV-coinfected patients
por: De Los Santos, Ignacio, et al.
Publicado: (2014)

Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C
por: Kondo, C, et al.
Publicado: (2016)

Impact of Specialty Pharmacy on Telaprevir-Containing 3-Drug Hepatitis C Regimen Persistence
por: Henderson, Rochelle R., et al.
Publicado: (2014)

Cost-effectiveness of Triple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2013)

Different Presentations of Patients with Transcobalamin II Deficiency: A Single-Center Experience from Turkey
por: Ünal, Selma, et al.
Publicado: (2019)

Comment on ‘polygamy, sexual behavior in a population under risk for prostate cancer diagnostic: an observational study from the black sea region in Turkey’
por: Özkidik, Mete, et al.
Publicado: (2018)

Comment from the Annals
por: Alzahrani, Ali. S.
Publicado: (2008)

The Effects of Boceprevir and Telaprevir on the Pharmacokinetics of Maraviroc: An Open-Label, Fixed-Sequence Study in Healthy Volunteers
por: Vourvahis, Manoli, et al.
Publicado: (2014)

Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study
por: Flamm, Steven L., et al.
Publicado: (2014)

Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C
por: Yamagiwa, Satoshi, et al.
Publicado: (2017)

Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection
por: Bichoupan, Kian, et al.
Publicado: (2017)

Timely Lessons From the Pandemic in Turkey
por: Yaman, Hakan
Publicado: (2020)

Rickettsialpox in Turkey
por: Ozturk, Mustafa K., et al.
Publicado: (2003)

Comment on: Fungal keratitis: The Aravind Experience
por: Galvis, Virgilio, et al.
Publicado: (2018)

REPLY BY THE AUTHORS: Comment on Polygamy, Sexual Behavior in a Population Under Risk for Prostate Cancer Diagnostic: An Observational Study From the Black Sea Region in Turkey
por: Cirakoglu, Abdullah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bv95g8vkqtscdj485amhuri335